Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Interchromosomal Translocations as a Means to Map Chromosome Territories in Breast Cancer.

Parl FF, Dupont WD, Crooke PS.

Cancer Inform. 2019 Apr 16;18:1176935119842573. doi: 10.1177/1176935119842573. eCollection 2019.

2.

Genomic-Epidemiologic Evidence That Estrogens Promote Breast Cancer Development.

Parl FF, Crooke PS, Plummer WD Jr, Dupont WD.

Cancer Epidemiol Biomarkers Prev. 2018 Aug;27(8):899-907. doi: 10.1158/1055-9965.EPI-17-1174. Epub 2018 May 22.

3.

Isolevuglandins as a gauge of lipid peroxidation in human tumors.

Yan HP, Roberts LJ, Davies SS, Pohlmann P, Parl FF, Estes S, Maeng J, Parker B, Mernaugh R.

Free Radic Biol Med. 2017 May;106:62-68. doi: 10.1016/j.freeradbiomed.2017.02.020. Epub 2017 Feb 9.

4.

Targeted multiplex imaging mass spectrometry with single chain fragment variable (scfv) recombinant antibodies.

Thiery G, Mernaugh RL, Yan H, Spraggins JM, Yang J, Parl FF, Caprioli RM.

J Am Soc Mass Spectrom. 2012 Oct;23(10):1689-96. Epub 2012 Aug 7.

5.

A multistage genetic association study identifies breast cancer risk loci at 10q25 and 16q24.

Higginbotham KS, Breyer JP, McReynolds KM, Bradley KM, Schuyler PA, Plummer WD, Freudenthal ME, Trentham-Dietz A, Newcomb PA, Parl FF, Sanders ME, Page DL, Egan KM, Dupont WD, Smith JR.

Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1565-73. doi: 10.1158/1055-9965.EPI-12-0386. Epub 2012 Jul 17.

6.

Estrogen metabolism and exposure in a genotypic-phenotypic model for breast cancer risk prediction.

Crooke PS, Justenhoven C, Brauch H; GENICA Consortium, Dawling S, Roodi N, Higginbotham KS, Plummer WD, Schuyler PA, Sanders ME, Page DL, Smith JR, Dupont WD, Parl FF.

Cancer Epidemiol Biomarkers Prev. 2011 Jul;20(7):1502-15. doi: 10.1158/1055-9965.EPI-11-0060. Epub 2011 May 24.

7.

A multistage association study identifies a breast cancer genetic locus at NCOA7.

Higginbotham KS, Breyer JP, Bradley KM, Schuyler PA, Plummer WD Jr, Freudenthal ME, Trentham-Dietz A, Newcomb PA, Sanders ME, Page DL, Parl FF, Egan KM, Dupont WD, Smith JR.

Cancer Res. 2011 Jun 1;71(11):3881-8. doi: 10.1158/0008-5472.CAN-10-2653. Epub 2011 May 24.

8.

A mathematical model for DNA damage and repair.

Crooke PS, Parl FF.

J Nucleic Acids. 2010 Jul 25;2010. pii: 352603. doi: 10.4061/2010/352603.

9.

Implementation of a closed-loop reporting system for critical values and clinical communication in compliance with goals of the joint commission.

Parl FF, O'Leary MF, Kaiser AB, Paulett JM, Statnikova K, Shultz EK.

Clin Chem. 2010 Mar;56(3):417-23. doi: 10.1373/clinchem.2009.135376. Epub 2009 Dec 29.

10.
11.

Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females.

Austin ED, Cogan JD, West JD, Hedges LK, Hamid R, Dawson EP, Wheeler LA, Parl FF, Loyd JE, Phillips JA 3rd.

Eur Respir J. 2009 Nov;34(5):1093-9. doi: 10.1183/09031936.00010409. Epub 2009 Apr 8.

12.

Estrogen metabolism and breast cancer: a risk model.

Parl FF, Dawling S, Roodi N, Crooke PS.

Ann N Y Acad Sci. 2009 Feb;1155:68-75. doi: 10.1111/j.1749-6632.2008.03676.x. Review.

13.

Carcinogen-induced histone alteration in normal human mammary epithelial cells.

Bradley C, van der Meer R, Roodi N, Yan H, Chandrasekharan MB, Sun ZW, Mernaugh RL, Parl FF.

Carcinogenesis. 2007 Oct;28(10):2184-92. Epub 2007 Apr 29.

PMID:
17468514
14.

Recombinant antibody piezoimmunosensors for the detection of cytochrome P450 1B1.

Shen Z, Yan H, Parl FF, Mernaugh RL, Zeng X.

Anal Chem. 2007 Feb 15;79(4):1283-9.

15.

Cytochrome P450 1B1-mediated estrogen metabolism results in estrogen-deoxyribonucleoside adduct formation.

Belous AR, Hachey DL, Dawling S, Roodi N, Parl FF.

Cancer Res. 2007 Jan 15;67(2):812-7.

16.

Calcium-phosphorus product and troponin-T values in renal failure.

Wrenn K, Blair R, Parl FF, Schleicher R.

Am J Emerg Med. 2006 Nov;24(7):836-8.

PMID:
17098107
17.

Meta- and pooled analyses of the cytochrome P-450 1B1 Val432Leu polymorphism and breast cancer: a HuGE-GSEC review.

Paracchini V, Raimondi S, Gram IT, Kang D, Kocabas NA, Kristensen VN, Li D, Parl FF, Rylander-Rudqvist T, Soucek P, Zheng W, Wedren S, Taioli E.

Am J Epidemiol. 2007 Jan 15;165(2):115-25. Epub 2006 Oct 19. Review.

PMID:
17053044
18.

Estrogens, enzyme variants, and breast cancer: a risk model.

Crooke PS, Ritchie MD, Hachey DL, Dawling S, Roodi N, Parl FF.

Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1620-9.

19.

Mitochondrial DNA G10398A polymorphism and invasive breast cancer in African-American women.

Canter JA, Kallianpur AR, Parl FF, Millikan RC.

Cancer Res. 2005 Sep 1;65(17):8028-33.

20.

Glutathione S-transferase genotypes and cancer risk.

Parl FF.

Cancer Lett. 2005 Apr 28;221(2):123-9. Review.

PMID:
15808397
21.

Immunohistochemical expression of estrogen receptor in enlarged lobular units with columnar alteration in benign breast biopsies: a nested case-control study.

McLaren BK, Gobbi H, Schuyler PA, Olson SJ, Parl FF, Dupont WD, Page DL.

Am J Surg Pathol. 2005 Jan;29(1):105-8.

PMID:
15613861
22.

Estrogen receptor genotypes and haplotypes associated with breast cancer risk.

Gold B, Kalush F, Bergeron J, Scott K, Mitra N, Wilson K, Ellis N, Huang H, Chen M, Lippert R, Halldorsson BV, Woodworth B, White T, Clark AG, Parl FF, Broder S, Dean M, Offit K.

Cancer Res. 2004 Dec 15;64(24):8891-900.

23.

Breast cancer risk associated with estrogen receptor expression in epithelial hyperplasia lacking atypia and adjacent lobular units.

Gobbi H, Dupont WD, Parl FF, Schuyler PA, Plummer WD, Olson SJ, Page DL.

Int J Cancer. 2005 Feb 20;113(5):857-9.

24.
25.

Glutathione S-transferases M1, T1, and P1 and breast cancer: a pooled analysis.

Vogl FD, Taioli E, Maugard C, Zheng W, Pinto LF, Ambrosone C, Parl FF, Nedelcheva-Kristensen V, Rebbeck TR, Brennan P, Boffetta P.

Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1473-9.

26.

Association of metabolic gene polymorphisms with tobacco consumption in healthy controls.

Smits KM, Benhamou S, Garte S, Weijenberg MP, Alamanos Y, Ambrosone C, Autrup H, Autrup JL, Baranova H, Bathum L, Boffetta P, Bouchardy C, Brockmoller J, Butkiewicz D, Cascorbi I, Clapper ML, Coutelle C, Daly AK, Muzi G, Dolzan V, Duzhak TG, Farker K, Golka K, Haugen A, Hein DW, Hildesheim A, Hirvonen A, Hsieh LL, Ingelman-Sundberg M, Kalina I, Kang D, Katoh T, Kihara M, Ono-Kihara M, Kim H, Kiyohara C, Kremers P, Lazarus P, Le Marchand L, Lechner MC, London S, Manni JJ, Maugard CM, Morgan GJ, Morita S, Nazar-Stewart V, Kristensen VN, Oda Y, Parl FF, Peters WH, Rannug A, Rebbeck T, Pinto LF, Risch A, Romkes M, Salagovic J, Schoket B, Seidegard J, Shields PG, Sim E, Sinnett D, Strange RC, Stucker I, Sugimura H, To-Figueras J, Vineis P, Yu MC, Zheng W, Pedotti P, Taioli E.

Int J Cancer. 2004 Jun 10;110(2):266-70.

27.

Association of homozygous wild-type glutathione S-transferase M1 genotype with increased breast cancer risk.

Roodi N, Dupont WD, Moore JH, Parl FF.

Cancer Res. 2004 Feb 15;64(4):1233-6.

28.

Increased prevalence of the HFE C282Y hemochromatosis allele in women with breast cancer.

Kallianpur AR, Hall LD, Yadav M, Christman BW, Dittus RS, Haines JL, Parl FF, Summar ML.

Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):205-12.

29.
30.

Multiple mechanisms of estrogen receptor gene repression contribute to ER-negative breast cancer.

Parl FF.

Pharmacogenomics J. 2003;3(5):251-3. No abstract available.

PMID:
14583793
31.

Methoxyestrogens exert feedback inhibition on cytochrome P450 1A1 and 1B1.

Dawling S, Roodi N, Parl FF.

Cancer Res. 2003 Jun 15;63(12):3127-32.

32.

Metabolic gene polymorphism frequencies in control populations.

Garte S, Gaspari L, Alexandrie AK, Ambrosone C, Autrup H, Autrup JL, Baranova H, Bathum L, Benhamou S, Boffetta P, Bouchardy C, Breskvar K, Brockmoller J, Cascorbi I, Clapper ML, Coutelle C, Daly A, Dell'Omo M, Dolzan V, Dresler CM, Fryer A, Haugen A, Hein DW, Hildesheim A, Hirvonen A, Hsieh LL, Ingelman-Sundberg M, Kalina I, Kang D, Kihara M, Kiyohara C, Kremers P, Lazarus P, Le Marchand L, Lechner MC, van Lieshout EM, London S, Manni JJ, Maugard CM, Morita S, Nazar-Stewart V, Noda K, Oda Y, Parl FF, Pastorelli R, Persson I, Peters WH, Rannug A, Rebbeck T, Risch A, Roelandt L, Romkes M, Ryberg D, Salagovic J, Schoket B, Seidegard J, Shields PG, Sim E, Sinnet D, Strange RC, Stücker I, Sugimura H, To-Figueras J, Vineis P, Yu MC, Taioli E.

Cancer Epidemiol Biomarkers Prev. 2001 Dec;10(12):1239-48.

33.
34.

No elevation in long-term breast carcinoma risk for women with fibroadenomas that contain atypical hyperplasia.

Carter BA, Page DL, Schuyler P, Parl FF, Simpson JF, Jensen RA, Dupont WD.

Cancer. 2001 Jul 1;92(1):30-6.

PMID:
11443606
35.

Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer.

Ritchie MD, Hahn LW, Roodi N, Bailey LR, Dupont WD, Parl FF, Moore JH.

Am J Hum Genet. 2001 Jul;69(1):138-47. Epub 2001 Jun 11.

36.

Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer.

Nass SJ, Herman JG, Gabrielson E, Iversen PW, Parl FF, Davidson NE, Graff JR.

Cancer Res. 2000 Aug 15;60(16):4346-8.

37.
38.

Estrogen replacement therapy in women with a history of proliferative breast disease.

Dupont WD, Page DL, Parl FF, Plummer WD Jr, Schuyler PA, Kasami M, Jensen RA.

Cancer. 1999 Mar 15;85(6):1277-83.

PMID:
10189132
39.

Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer.

Bailey LR, Roodi N, Dupont WD, Parl FF.

Cancer Res. 1998 Nov 15;58(22):5038-41. Erratum in: Cancer Res 1999 Mar 15;59(6):1388.

40.

Mapping of ER gene CpG island methylation-specific polymerase chain reaction.

Lapidus RG, Nass SJ, Butash KA, Parl FF, Weitzman SA, Graff JG, Herman JG, Davidson NE.

Cancer Res. 1998 Jun 15;58(12):2515-9.

41.

Breast cancer and CYPIA1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African Americans.

Bailey LR, Roodi N, Verrier CS, Yee CJ, Dupont WD, Parl FF.

Cancer Res. 1998 Jan 1;58(1):65-70.

42.

Impact of managed care on the economics of laboratory operation in an academic medical center.

Benge H, Bodor GS, Younger WA, Parl FF.

Arch Pathol Lab Med. 1997 Jul;121(7):689-94.

PMID:
9240903
43.

High-mobility group (HMG) protein HMG-1 and TATA-binding protein-associated factor TAF(II)30 affect estrogen receptor-mediated transcriptional activation.

Verrier CS, Roodi N, Yee CJ, Bailey LR, Jensen RA, Bustin M, Parl FF.

Mol Endocrinol. 1997 Jul;11(8):1009-19.

PMID:
9212049
44.

Methylation of estrogen and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors.

Lapidus RG, Ferguson AT, Ottaviano YL, Parl FF, Smith HS, Weitzman SA, Baylin SB, Issa JP, Davidson NE.

Clin Cancer Res. 1996 May;2(5):805-10.

45.

Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer.

Roodi N, Bailey LR, Kao WY, Verrier CS, Yee CJ, Dupont WD, Parl FF.

J Natl Cancer Inst. 1995 Mar 15;87(6):446-51.

PMID:
7861463
46.

Long-term risk of breast cancer in women with fibroadenoma.

Dupont WD, Page DL, Parl FF, Vnencak-Jones CL, Plummer WD Jr, Rados MS, Schuyler PA.

N Engl J Med. 1994 Jul 7;331(1):10-5.

47.

Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells.

Ottaviano YL, Issa JP, Parl FF, Smith HS, Baylin SB, Davidson NE.

Cancer Res. 1994 May 15;54(10):2552-5.

48.

p53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment.

Caleffi M, Teague MW, Jensen RA, Vnencak-Jones CL, Dupont WD, Parl FF.

Cancer. 1994 Apr 15;73(8):2147-56.

PMID:
8156519
49.

Microsatellite instability and loss of heterozygosity in breast cancer.

Yee CJ, Roodi N, Verrier CS, Parl FF.

Cancer Res. 1994 Apr 1;54(7):1641-4.

Supplemental Content

Support Center